The COVID-19 impact to the heart is far more prevalent than we recognize today. In fact, a study published in 2020 shows 78% of COVID-19 patients had some form of cardiac involvement following recovery, and 60% had ongoing myocardial inflammation.1 The majority of patients had recovered at home, and none had prior known cardiovascular issues. As a result, patients with past COVID diagnoses–especially those with preexisting heart conditions–may be at a higher risk of developing worsening cardiovascular complications, such as myocarditis and pericarditis.2 This highlights the need for highly sensitive, rapid and safe diagnostics to monitor and manage the potential long-term effects of COVID-19 on the heart.
MyoStrain provides a sensitive, accurate and COVID-safe heart health assessment for patients recovering from COVID-19. Complete in under 10 minutes, MyoStrain gives clinicians novel cardiac insights to detect the early cardiac effects of COVID-19, enabling opportunities to monitor changes in heart health over time and optimize treatment for improved outcomes and quality of life.